A Phase 2 interventional study of tamsulosin in Lower Urinary Tract Symptoms, sponsored by Boehringer Ingelheim. Completed at 18 sites in United States. Open to male participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2020-03-27.
Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing tamsulosin in Lower Urinary Tract Symptoms — 5 open to participants now, 5 under way, none of them phase 3. Tamsulosin · Lower Urinary Tract Symptoms.
Among the 22 studies testing tamsulosin in Lower Urinary Tract Symptoms, this one is the 6th largest by enrollment, is the only one that started in 2012, is one of 4 in phase 2, and was the 6th registered.
417 studies on the registry are indexed under Lower Urinary Tract Symptoms; 110 are open to participants now.
Browse Lower Urinary Tract Symptoms studies →5 of the 22 studies testing tamsulosin in Lower Urinary Tract Symptoms are open now, in 4 countries. Recruiting first, the newest first:
Ain Shams University · Sites in Egypt
Ages 45+
Centre Hospitalier Universitaire de Nīmes · Sites in France
Ages 18+ · Women only
Azienda Ospedaliero Universitaria Maggiore della Carita · Sites in Italy
Ages 40+ · Men only · Healthy volunteers
Ain Shams University · Sites in Egypt
Ages 50+ · Men only
Peking University First Hospital · Sites in China
Ages 40–85 · Men only
By country, each count listing its studies:
Tamsulosin: first FDA approval 1997 (FLOMAX). What it is approved for, and how studies give it, is on its page →
Of the 59 Lower Urinary Tract Symptoms studies recruiting now, 39 (66%) set no upper age limit and 11 (19%) stop at 75 or younger; 7 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 100 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 4 · Phase 4 9
First in 2001; this study’s year is marked. 1 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 689 is above the median of 100 across 272 interventional studies indexed under Lower Urinary Tract Symptoms.
Median enrollment 136 across the 22 interventional studies. Of the 17 that completed or were terminated, 8 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 22 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Boehringer Ingelheim has 2 studies filed under Lower Urinary Tract Symptoms — fewer than ten, so there is no comparison to draw.
1 of the studies testing tamsulosin in Lower Urinary Tract Symptoms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07722884Ain Shams UniversityTamsulosin Monotherapy Versus Combination Therapy With Tadalafil (2.5 mg vs 5 mg) in Managing Male LUTS Secondary to BPH | 2027-01-01 |
Add it to your calendar (.ics) → With an account.
Among the 22 studies testing tamsulosin in Lower Urinary Tract Symptoms, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Multicenter trial conducted in Pharmacy retail centers
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
patients will take drug for 8 weeks in this exploratory study
Drug: tamsulosin
0.4 mg
Percentage of Participants Who Appropriately Followed the Label Instructions
Includes subjects who reported: 1. No improvement in urinary symptoms and stopped taking product, 2. Reported worsening of urinary symptoms and stopped taking the product, 3. Reported a new urinary symptom and stopped taking the product, 4. Reported no "Stop Use" condition and never took more than 1 capsule on any given day, 5. Reported a "Stop Use" condition and contacted a provider.
Time frame: 8 weeks
Percentage of Participants Who Took no More Than One Capsule Per Day
Percentage of participants who took no more than one capsule per day
Time frame: 8 weeks
Percentage of "Use-Days" for All Participants Who Took no More Than One Capsule Per Day
"Use-day" was defind as a calendar day for which data were available regarding use or non-use.
Time frame: 8 weeks
Percentage of Participants < 45 Years of Age Who Spoke to a Doctor During the Actual Use Phase
Includes participants who: 1. were less than 45 years of age at enrollment, and 2. spoke to a doctor during the actual use phase.
Time frame: 8 weeks
Percentage of Participants Who Are Potentially at Risk of Harm by Incorrectly Selecting to Use the Study Product Out of the Total Study Population
Percentage of participants who are potentially at risk of harm by incorrectly selecting to use the study product out of the total study population
Time frame: 8 weeks
Percentage of Participants Who Have a Correct Self-selection Response Out of the Total Study Population
Percentage of participants who have a correct self-selection response as defined by the "Uses", "Allergy alert", and "Do Not Use" sections of the Drug Facts Label.
Time frame: 8 weeks
Study had 2 parts: In part 1 participants reviewed the product label and responded to a question about whether the product is appropriate for them to use (self-selection), selected participants then entered part 2 where they recieved study product (actual use).
| Milestone | All Subjects |
|---|---|
| Started | 689 |
| Completed | 679 |
| Not completed | 10 |
| Withdrew: Withdrawal by subject | 10 |
| Milestone | All Subjects |
|---|---|
| Started | 389 |
| Completed | 369 |
| Not completed | 20 |
| Withdrew: Eligible but did not enter part 2 | 20 |
| Milestone | All Subjects |
|---|---|
| Started | 369 |
| Completed | 330 |
| Not completed | 39 |
| Withdrew: Withdrawal by subject | 21 |
| Withdrew: Adverse event | 6 |
| Withdrew: Lost to follow-up | 5 |
| Withdrew: Other than reason specified above | 7 |
Includes subjects who reported: 1. No improvement in urinary symptoms and stopped taking product, 2. Reported worsening of urinary symptoms and stopped taking the product, 3. Reported a new urinary symptom and stopped taking the product, 4. Reported no "Stop Use" condition and never took more than 1 capsule on any given day, 5. Reported a "Stop Use" condition and contacted a provider.
| Percentage of participants | Tamsulosin Hydrochloride |
|---|---|
| Percentage of Participants Who Appropriately Followed the Label Instructions | 85.4 |
Percentage of participants who took no more than one capsule per day
| Percentage of participants | Tamsulosin Hydrochloride |
|---|---|
| Percentage of Participants Who Took no More Than One Capsule Per Day | 93.7 (90.3 to 96.1) |
"Use-day" was defind as a calendar day for which data were available regarding use or non-use.
| Percentage of participants | Tamsulosin Hydrochloride |
|---|---|
| Percentage of "Use-Days" for All Participants Who Took no More Than One Capsule Per Day | 94.1 (90.9 to 96.2) |
Includes participants who: 1. were less than 45 years of age at enrollment, and 2. spoke to a doctor during the actual use phase.
| Percentage of participants | Tamsulosin Hydrochloride |
|---|---|
| Percentage of Participants < 45 Years of Age Who Spoke to a Doctor During the Actual Use Phase | 30.4 |
Percentage of participants who are potentially at risk of harm by incorrectly selecting to use the study product out of the total study population
| Percentage of participants | Tamsulosin Hydrochloride |
|---|---|
| Percentage of Participants Who Are Potentially at Risk of Harm by Incorrectly Selecting to Use the Study Product Out of the Total Study Population | 20.9 (17.9 to 24.2) |
Percentage of participants who have a correct self-selection response as defined by the "Uses", "Allergy alert", and "Do Not Use" sections of the Drug Facts Label.
| Percentage of participants | Tamsulosin Hydrochloride |
|---|---|
| Percentage of Participants Who Have a Correct Self-selection Response Out of the Total Study Population | 73.9 (70.5 to 77.2) |
Collected over 8 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| EVAL-SS | — | 10/679 (1.5%) | 26/679 (3.8%) |
| Treated Set | — | 10/351 (2.8%) | 26/351 (7.4%) |
| FAS-AUS | — | 9/321 (2.8%) | 22/321 (6.9%) |
| Event | EVAL-SS | Treated Set | FAS-AUS |
|---|---|---|---|
| AbscessInfections and infestations | 1/679 | 1/351 | 1/321 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/679 | 1/351 | 1/321 |
| Malignant melanomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/679 | 1/351 | 1/321 |
| Transient ischaemic attackNervous system disorders | 1/679 | 1/351 | 1/321 |
| Atrial flutterCardiac disorders | 1/679 | 1/351 | 1/321 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 1/679 | 1/351 | 1/321 |
| PancreatitisGastrointestinal disorders | 1/679 | 1/351 | 1/321 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 1/679 | 1/351 | 1/321 |
| Chest painGeneral disorders | 1/679 | 1/351 | 1/321 |
| Angina pectorisCardiac disorders | 1/679 | 1/351 | 0/321 |
| Event | EVAL-SS | Treated Set | FAS-AUS |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 26/679 | 26/351 | 22/321 |
Evaluable Analysis Set for Self-Selection (Eval-SS): All subjects who answered self-selection question, probing question and follow-up questions
| Age, Continuous(years) | All Subjects |
|---|---|
| Mean | 65.7 ± 13.2 |
| Sex: Female, Male(Participants) | All Subjects |
|---|---|
| Female | 0 |
| Male | 679 |
The record gives a start of Nov 2012, a primary completion of Mar 2013 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2020, 7 years after primary completion. A results delay was requested in Mar 2014.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tamsulosin
Lower Urinary Tract Symptoms →